Glenmark Gains U.S. FDA Approval for Fluticasone Aerosol with CGT Exclusivity
Filing Summary
Glenmark Specialty SA, a subsidiary of Glenmark Pharmaceuticals Ltd, has received final approval from the U.S. FDA for its Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation. This approval includes a 180-day Competitive Generic Therapy (CGT) exclusivity. The product is bioequivalent to GlaxoSmithKline’s FloVent® HFA Inhalation Aerosol. Glenmark plans to distribute the product in the U.S. starting March 2026. The FloVent® market had annual sales of approximately $520 million as of January 2026. This approval enhances Glenmark’s respiratory portfolio in the U.S. market.
Glenmark Specialty SA, a subsidiary of Glenmark Pharmaceuticals Ltd, has secured final approval from the U.S. FDA for its Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation. This approval includes a 180-day Competitive Generic Therapy (CGT) exclusivity, allowing Glenmark to be the first approved applicant for this product. The aerosol is deemed bioequivalent and therapeutically equivalent to the reference listed drug, FloVent® HFA Inhalation Aerosol, 44 mcg, by GlaxoSmithKline Intellectual Property Ltd.
The approval grants Glenmark a significant market opportunity in the U.S. respiratory segment. The FloVent® HFA Inhalation Aerosol market achieved annual sales of approximately $520 million for the 12-month period ending January 2026, according to IQVIA sales data. This exclusivity period allows Glenmark to capture market share without competition from other generic versions for 180 days upon commercialization.
The Fluticasone Propionate Inhalation Aerosol USP will be distributed in the U.S. by Glenmark Pharmaceuticals Inc., USA, starting in March 2026. The product is designed for the treatment of asthma and is part of Glenmark’s strategy to expand its respiratory portfolio. The CGT designation reflects the technical expertise required to develop complex inhalation therapies and underscores Glenmark’s commitment to providing quality and affordable respiratory treatments.
The market for respiratory therapies in the U.S. is significant, with a demand for cost-effective alternatives to branded medications. Glenmark’s entry into this market with a CGT exclusivity positions it strategically to meet this demand. The approval aligns with Glenmark’s focus on enhancing its presence in the U.S. pharmaceutical market, particularly in the respiratory segment.
The product will be available for distribution in March 2026, marking the beginning of the 180-day exclusivity period. Glenmark Pharmaceuticals Inc., USA, will handle the distribution, ensuring the product reaches healthcare providers and patients efficiently. This timeline is crucial for maximizing the benefits of the exclusivity period.
Glenmark Pharmaceuticals Ltd is a global pharmaceutical company focused on innovation and accessibility. The company develops a diversified portfolio across branded, specialty, generics, and consumer health products, with a particular emphasis on respiratory, dermatology, and oncology therapies. Glenmark operates 11 manufacturing facilities and six R&D centers worldwide, serving over 80 countries. The company is recognized among the top 100 biopharmaceutical companies globally by pharmaceutical sales.